Patent expiration to drive biosimilars market expansion to 2032
European Pharmaceutical Review
APRIL 11, 2024
As of September 2022, there were around 39 biosimilars approved and 22 marketed, the report stated. This has resulted in “increased competition and price pressure, driving the growth of the biosimilar market”. The latter of which is important in “gaining a competitive advantage”, the author noted. million by 2032, at 17.6
Let's personalize your content